Form 4: Actuate Therapeutics Director Receives Stock Option Grant

Director Roger Sawhney was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Roger Sawhney acquired 15,000 stock options in Actuate Therapeutics, Inc. (ACTU).
• The options have an exercise price of $2.42 per share.
• The grant date for these options is May 21, 2026.
• The options are set to expire on May 21, 2036.
• The options will vest in full on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.42 exercise price.

Future Outlook

The options vest in full on May 21, 2027, aligning the director's interest with the company's performance over the next year.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of 15,000 options is consistent with typical non-employee director compensation packages for small-cap biotechnology firms.
• Vesting schedules of one year are common for director equity awards in the industry.

Stakeholder Impact

• Minor potential dilution for shareholders if options are exercised in the future.

Next Steps

• Vesting of the 15,000 options on May 21, 2027.

Key Dates

Keywords

Actuate Therapeutics, ACTU, Form 4, Insider Trading, Stock Options, Director Compensation